TSX:BHC (Bausch Health Companies Inc.)

About BHC

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
  • Bausch Health Companies Inc. (TSX: BHC) Latest News

    The Motley Fool
    Investing

    Will Donald Trump Give Valeant Pharmaceuticals Intl Inc. a Much-Needed Lifeline?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) stock jumped 28% this week. What’s brewing?

    Read more »

    The Motley Fool
    Investing

    Is Valeant Pharmaceuticals Intl Inc. a Viable Investment Opportunity?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to chip away at a staggering amount of debt and transition to a more…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. vs. Jean Coutu Group PJC Inc.: Is the Drug Maker or Drug Retailer a Buy?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is a drug producer, while Jean Coutu Group PJC Inc. (TSX:PJC.A) is a drug retailer.…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: When Is a Good Time to Invest?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to achieve its goal of paying down its debt, but there's a lot of…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. Takes Another Step Closer to Death

    After unloading another business, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is another step closer to being crippled by the interest expenses.

    Read more »

    The Motley Fool
    Investing

    Get ‘Em While They’re Hot: Shares of Valeant Pharmaceuticals Intl Inc. Climb

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) has continued to make headway towards its proposed $5 billion debt-repayment schedule set for February…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc. May Raise Another US$2 Billion to Pay Back Debt: Time to Buy?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) made another deal. Is Valeant well positioned to meet its goal of debt repayment? Is…

    Read more »

    The Motley Fool
    Investing

    Contrarian Investors: Don’t Expect a Sudden Rebound in Valeant Pharmaceuticals Intl Inc.

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) appears to be getting cheaper by the day. Is it finally time to initiate a…

    Read more »

    The Motley Fool
    Investing

    Don’t Miss Out on This Bargain Stock Before it’s Too Late

    While Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) doesn't currently pay a dividend, the company has a very healthy cash flow stream,…

    Read more »

    hospital beds
    Dividend Stocks

    Invest in the Healthcare Industry to Take Advantage of Demographic Trends

    The aging population means that Chartwell Retirement Residences (TSX:CSH.UN) and Extendicare Inc. (TSX:EXE) are in the right business for the…

    Read more »

    The Motley Fool
    Investing

    Valeant Pharmaceuticals Intl Inc.: Is the Turnaround Working?

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to take the right steps, but a turnaround will take time.

    Read more »

    The Motley Fool
    Investing

    An Update on the Solvency Issues at Valeant Pharmaceuticals Intl Inc.

    After two very difficult years, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is simply two years closer to bankruptcy.

    Read more »